louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05404425: Non-severe Traumatic Injuries Evaluation Using smartPhone Camera for Extra-hospital Regulation
Official title: Non-severe Traumatic Injuries Evaluation Using smartPhone Camera for Extra-hospital Regulation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild Traumatic Injury
Pre-hospital Dispatching
Visioconference
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2022-06-03
Enrollment: 168
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Photography teletransmission allow a better and optimized dispatching of patients calling an Emergency Medical Call Center (EMCC) for a mild traumatic injury. It has previously been studied for patients to whom an ambulance was sent and therefore presumed to be older or with co-morbidities. The present trial aim to evaluate in the general population, the effect of a smartphone-mediated visioconference in the dispatching of patients calling an EMCC for mild traumatic injury.


Eligibility criteria: Inclusion Criteria:

* adult patients (≥18 years of age),
* free of will (not under any guardianship or liberty privation),
* suffering from Mild Traumatic Injury,
* availability of a smartphone with internet connection for the patients or witness,
* consenting to participate in the study

Exclusion Criteria:

* severe trauma requiring immediate medical assistance
* trauma associated with head injury, on antiplatelet therapy (APT) or anti-coagulation therapy (ACT)

Primary outcomes:
measure: Proportion of patients dispatched elsewhere than to the nearest hospital
timeFrame: 1 year
Secondary outcomes:
measure: Under-triage
timeFrame: 1 year
measure: Over-triage
timeFrame: 1 year
Other outcomes:
Locations:
city: Poitiers
country: France
facility: Chu of Poitiers
Study officials:
References:
Clinical trial NCT00981825: Efficacy of Salivary Bacteria and Post Brushing
Official title: Efficacy of Salivary Bacteria and Post Brushing
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Salivary Bacteria Levels
Lead sponsor: Colgate Palmolive
Sponsor class: INDUSTRY
First posted: 2009-09-22
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Research study to compare the effects of brushing with two commercially available toothpastes on salivary bacteria after brushing


Eligibility criteria: Inclusion Criteria:

* Male or female volunteers 18-65 years of age
* Good general health
* Must sign informed consent form
* Must discontinue oral hygiene on the mornings of each appointment and between sampling periods.
* No history of allergy to personal care consumer products, or their ingredients, relevant to any ingredient in the test products as determined by the dental/medical professional monitoring the study.

Exclusion Criteria:

* Medical condition which requires pre-medication prior to dental procedures/visits
* Medical condition which precludes eating/drinking for 12 hrs.
* History of allergy to common dentifrice ingredients
* Subjects unable or unwilling to sign the informed consent form.
* Moderate or advanced periodontal disease.
* 2 or more decayed untreated dental sites at screening.
* Other disease of the hard or soft oral tissues.
* Impaired salivary function (e.g. Sjogren's syndrome or head and neck irradiation).
* Use of medications that can currently affect salivary flow
* Current use of antibiotics
* Use of antibiotics or antimicrobial drugs within 30 days prior to study visit #1.
* Pregnant or nursing women.
* Participation in any other clinical study within 30 days prior to enrollment into this study.
* Use of tobacco products
* Subjects who must receive dental treatment during the study dates.
* Current use of Antibiotics for any purpose.
* Immune compromised individuals (HIV,AIDS, immuno suppressive drug therapy)

Primary outcomes:
measure: CFU (Colony Forming Units)
timeFrame: 4 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Mumbai
country: India
facility: India GTC, Colgate Palmolive(I) ltd
Study officials:
name: Neelim Utgikar, DDS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03139825: Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study
Official title: Connectivity and Social Cognition in Adolescent Girls With Borderline Personality Disorder, a Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Adolescent Behavior
Borderline Personality Disorder
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-05-04
Enrollment: 0
Sex: ALL
Minimum age (years): 14
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The disruption of social cognition associated with borderline personality disorder (BPD), and more specifically categorization of facial emotions, remains largely under-studied, despite the high frequency of this pathology in the clinical population. The first results differ from the observations made in adults and this confirms the relevance of studying this theme specifically in adolescence. On the cognitive level, there is a disturbance of the detection and the categorization of the facial emotions in the TPL. The characteristics of this disturbance and its possible association with an attack on the connectivity of the brain remain unknown in adolescence. No functional imaging studies are published in adolescent TPL. This pilot bimodal functional imaging study EEG-NIRS aims to collect preliminary and feasibility data to support a response to upcoming PHRC competitions and eventually offer a science thesis opportunity.


Eligibility criteria: Inclusion Criteria:

* Adolescents 14-17 years of age with suicidal behavior and a borderline personality disorder for whom consent is obtained from parental authority,
* Affiliation to Social Security

Exclusion Criteria:

* Intellectual disability, psychopathy, delusional or concomitant major depression

Primary outcomes:
measure: Analysis by functional imaging study of the characteristics of disorders of personalities and its possible association with an attack on connectivity of the brain
timeFrame: 3 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT03853525: A Study to Gain Information How Well Dexpanthenol Dermal Spray Helps the Skin to Recover After Laser Hair Removal in the Groin and Intimate Area
Official title: Safety and Efficacy Evaluation of the Use of Bepantol® Derma Spray After Laser Depilation in the Inguinal Region in Adult Women - 21 Days Use at Home
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Skin Recovery
Keywords: Dermal spray
Laser depilation
Skin hydration
Consumer satisfaction
Sensorial perception
Lead sponsor: Bayer
Sponsor class: INDUSTRY
First posted: 2019-02-25
Enrollment: 35
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In this study, researchers want to learn more about the effect of dexpanthenol dermal spray on skin recovery after a dermatological procedure for hair removal (laser depilation) in the groin and intimate area in adult women.

After the hair removal procedure, participants will return within 3 weeks for 3 visits to the study center to investigate the skin condition such as redness, irritation, softness of skin and possible side effects. Study participants will also be asked about their general acceptance of dexpanthenol dermal spray.

Detailed description: The primary objective is to evaluate the efficacy of the test product to aid skin recovery after lasering depilation in the intima and inguinal region.

Secondary objectives comprise clinical efficacy with respect to skin hydration, softness, vitality, appearance etc. and skin recovery, consumer judgement of product performance and acceptability, and safety.

Eligibility criteria: Inclusion Criteria:

* Phototypes I and II according to the Fitzpatrick scale
* Participants willing to have a dermatological procedure (laser depilation) in the inguinal region to remove hairs in the region

Exclusion Criteria:

* Pathologies and/or skin injuries, such as psoriasis, sensitive skin, skin cancer, atopic dermatitis or other medical criteria to be considered at the time of evaluation
* Hyperpigmentations in the test area that interfere with the evaluation of possible reactions (vascular malformations, scars, increase of pilosity and large amount of nevi)
* Pathologies and/or active skin injuries (local and/or disseminated) in the evaluation area

Primary outcomes:
measure: Transepidermal water loss by TEWL probe
timeFrame: Up to 23 days
Secondary outcomes:
measure: Skin properties of the participants
timeFrame: Up to 23 days
measure: Treatment satisfaction
timeFrame: Up to 23 days
measure: Product evaluation
timeFrame: Up to 23 days
measure: Number of adverse events by dermatological evaluation
timeFrame: Up to 23 days
measure: Severity of adverse events by dermatological evaluation
timeFrame: Up to 23 days
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Medcin Instituto da Pele
Study officials:
References:
Clinical trial NCT00511225: Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease
Official title: Effects of Oral Cholecalciferol (Vitamin D3) on Bone Health, Neuromuscular Function, and Quality of Life in Adults With Chronic Kidney Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: End Stage Renal Disease
Keywords: dialysis
Vitamin D
Lead sponsor: Creighton University
Sponsor class: OTHER
Collaborators: name: Dialysis Clinic, Inc.
First posted: 2007-08-03
Enrollment: 47
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Will oral vitamin improve strength, bone quality, pain and quality of life. This is a double blind, randomized placebo controlled study using 10,000 IU of cholecalciferol vs placebo.

Detailed description: The proposed study is be a randomized, double-blind, placebo-controlled trial of supplementation with oral vitamin D3.

Each subject will take a once-weekly capsule containing vitamin D3 or a an identical-appearing placebo for a treatment period of 15 weeks.

Subjects will be assessed for Bone pain and tenderness, Neuromuscular function, physical performance score, and Quality of life assessment.

A subset of subjects will have bone biopsies performed before and after intervention.

Eligibility criteria: Inclusion Criteria:

* On dialysis
* Likely to be able to complete the study
* At least minimally ambulatory, with or without a walking aid (i.e., cane or walker)
* Able to complete the various questionnaires interactively with the research nurse
* Venous access that can be accomplished without unusual difficulty.

Primary outcomes:
measure: change in physical performance score
timeFrame: 15 weeks
Secondary outcomes:
measure: Bone pain and tenderness
timeFrame: 15 weeks
measure: Neuromuscular function tests
timeFrame: 15 weeks
measure: Quality of life assessment
timeFrame: 15 weeks
Other outcomes:
Locations:
city: Omaha
country: United States
facility: Creighton University
state: Nebraska
Study officials:
affiliation: Creighton University
name: Richard Lund, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Graeff-Armas LA, Kaufmann M, Lyden E, Jones G. Serum 24,25-dihydroxyvitamin D3 response to native vitamin D2 and D3 Supplementation in patients with chronic kidney disease on hemodialysis. Clin Nutr. 2018 Jun;37(3):1041-1045. doi: 10.1016/j.clnu.2017.04.020. Epub 2017 Apr 30.
citation: Armas LA, Andukuri R, Barger-Lux J, Heaney RP, Lund R. 25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis. Clin J Am Soc Nephrol. 2012 Sep;7(9):1428-34. doi: 10.2215/CJN.12761211. Epub 2012 Jul 12.
Clinical trial NCT01728025: Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Long QT Syndrome Type 3
Keywords: Long QT syndrome
Ranolazine
Lead sponsor: Tel-Aviv Sourasky Medical Center
Sponsor class: OTHER_GOV
First posted: 2012-11-16
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.


Eligibility criteria: Inclusion Criteria:

* Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene
* Corrected QT interval \> 460 msec

Exclusion Criteria:

* Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors)

Primary outcomes:
measure: Number of participants with syncope and/or documented ventricular arrhythmia
timeFrame: 5 years
Secondary outcomes:
measure: Change in corrected QT interval
timeFrame: within 30 days of initiation of Ranolazine treatment
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Medical Center
Study officials:
References:
citation: Moss AJ, Zareba W, Schwarz KQ, Rosero S, McNitt S, Robinson JL. Ranolazine shortens repolarization in patients with sustained inward sodium current due to type-3 long-QT syndrome. J Cardiovasc Electrophysiol. 2008 Dec;19(12):1289-93. doi: 10.1111/j.1540-8167.2008.01246.x. Epub 2008 Jul 25.
citation: Lindegger N, Hagen BM, Marks AR, Lederer WJ, Kass RS. Diastolic transient inward current in long QT syndrome type 3 is caused by Ca2+ overload and inhibited by ranolazine. J Mol Cell Cardiol. 2009 Aug;47(2):326-34. doi: 10.1016/j.yjmcc.2009.04.003. Epub 2009 Apr 14.
citation: Chorin E, Hu D, Antzelevitch C, Hochstadt A, Belardinelli L, Zeltser D, Barajas-Martinez H, Rozovski U, Rosso R, Adler A, Benhorin J, Viskin S. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol. 2016 Oct;9(10):e004370. doi: 10.1161/CIRCEP.116.004370.
Clinical trial NCT01175525: Treatment of Acute Stroke With Cromolyn(Single Dose)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Acute Stroke
Lead sponsor: Wolfson Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-08-05
Sex: ALL
Minimum age (years): 20
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Intervention model: PARALLEL

Brief summary: Mastocytes were proven to have a central rule in their development of the lipoid plaque of the vascular system. Mastocytes also has an important role in the stabilisation of the plaque in the building of the brain barrier. Different animal studies show that the inhibition of the mastocyte activity decreases significantly the risk of secondary bleeding post ischaemic stroke.It was also shown that post stroke inflammation process was also blocked by the inhibition of mastocytes.Other studies showed up to 100% decrease in the brain barrier disruption and post stroke oedema, after treatment with mastocyte inhibitors.

Cromolyn is a synthetic drug which has an anti-allergic effect by inhibition of the mastocytes. This drug is a well known,safe drug and is the main sub-substance that was used in the previously mentioned studies.


Eligibility criteria: Inclusion Criteria:

1. Infarction of the anterior Circulation system.
2. Both genders
3. Age \> 20 years
4. NIHSS \> 5 -

Exclusion Criteria:

1. Non- ischaemic stroke
2. Additional disease of the CNS
3. Known allergy to cromolyn
4. Diseae of mastocytosis
5. Renal or Hepatic failure (acute or chronic)
6. Inability to sign consent form (dementia or sensory aphasia)
7. Lacunar infarctions
8. INfarction present in cerebellum or brain stem -

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Holon
country: Israel
facility: Edith wolfson medical Center
Study officials:
affiliation: Wolfson Medical Center
name: Yair Lampl, Neurologist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04230525: Body Impedance Method in Patients Undergoing Urgent and Elective Cesarian Section
Official title: Noninvasive Evaluation of Hemodynamics by Using Body Impedance Method in Patients Undergoing Urgent and Elective Cesarian Section
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Cesarean Section Complications
Lead sponsor: Gaziosmanpasa Research and Education Hospital
Sponsor class: OTHER_GOV
First posted: 2020-01-18
Enrollment: 95
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Emergency or elective cesarean patients, which are between 18-45 years of age

Brief summary: Independent form anesthetic methods, during C/S, considering both maternal and fetal conditions, some crucial hemodynamic changes can appear and can be claimed non invasively with the whole body bioimpedance. In this research, any kind of hemodynamic difference between this method and urgent or elective C/S case will be detected and the clinic pursuit can be developed creating an advantage in favor of both maternal and fetal conditions.

Detailed description: Independent form anesthetic methods, during C/S, considering both maternal and fetal conditions, some crucial hemodynamic changes can appear and can be claimed non invasively with the whole body bioimpedance. In this research, any kind of hemodynamic difference between this method and urgent or elective C/S case will be detected and the clinic pursuit can be developed creating an advantage in favor of both maternal and fetal conditions. Under general anesthesia, measuring the hemodynamic changes with the method of non-invasive whole-body bioimpedance system during C/S.

Detection of in which phase of operations the potential changes densify and differences between urgent and elective conditions non invasively.

Eligibility criteria: Inclusion Criteria:

* Must be scheduled for elective or emergency cesarean section

Exclusion Criteria:

* History of cardiac surgery, and advanced cardiac valvular disease

Primary outcomes:
measure: MAP
timeFrame: 1, 5, 15, and 30 minutes following the induction of the anesthesia
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Gaziosmanpaşa TREH
state: Gaziosmanpaşa
Study officials:
References:
Clinical trial NCT03601325: Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome
Official title: Acute Pancreatitis: Study of Possible Etiologies and Risk Factors Affecting Outcome (Hospital Based Study)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pancreatitis
Keywords: pancreatitis
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All patients admitted in assuit university hospital during the period of the study and diagnosed as acute pancreatitis

Brief summary: This study is to assess the frequency of different etiologies of acute pancreatitis in our locality \& assess the effect of different risk factors on outcome of the patients.


Eligibility criteria: Inclusion Criteria:

-

Diagnosis of acute pancreatitis according to the following: the presence of two of the three following criteria:

* abdominal pain consistent with the disease
* serum amylase and or lipase greater than three times the upper limit of normal
* characteristic findings from abdominal imaging Contrast-enhanced computed tomographic (CECT) and or magnetic resonance imaging (MRI) of the pancreas

Exclusion Criteria:

* No exclusion criteria .

Primary outcomes:
measure: The frequency of different etiologies of AP in our locality
timeFrame: 1 year
Secondary outcomes:
measure: Outcome of the patients according to the Atlanta Classification 2012 revision
timeFrame: 1 year
measure: Hospital duration of stay
timeFrame: 1 year
measure: Rate of transfer to ICU
timeFrame: 1 year
measure: Mortality
timeFrame: 1 year
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Ahmed Mohammed Abu-Elfatth
Study officials:
affiliation: Assiut University
name: Ashraf Osman, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01484925: BETERNet Notch Signaling and Novel Biomarkers for Barretts Esophagus
Official title: Notch Signaling and Novel Biomarkers for Barretts Esophagus
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Barrett's Esophagus
Keywords: Barrett's esophagus
Lead sponsor: Abramson Cancer Center at Penn Medicine
Sponsor class: OTHER
First posted: 2011-12-05
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with Barretts Esophagus with and without associated dysplasia or cancer and controls with and without gastro-esophageal reflux.

Brief summary: This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Patients undergoing an upper endoscopy will be asked to complete a gastroesophageal reflux disease (GERD) questionnaire, provide a blood sample and allow additional biopsies to be taken during the procedure.

Detailed description: This research study hopes to identify new molecular markers in the tissue of Barrett's esophagus that will help physicians better understand and manage this condition. Currently there is very little understanding as to how Barrett's esophagus develops and why some people with Barrett's esophagus go on to develop esophageal cancer. The purpose of this study is to develop a better understanding of how these processes occur. The investigators also hope to use the information from this study to identify new molecular markers that the investigators can use to better determine who will or will not go on to develop esophageal cancer. Patients who have been diagnosed in the past with Barrett's esophagus will be asked to participate. Patients without Barrett's esophagus will be asked to take part so that the investigators can compare tissue from patients without the conditions to those with the conditions.

Eligibility criteria: Inclusion Criteria:

For BE patients:

* History of histologically confirmed BE, defined as endoscopically-suspected BE with intestinal metaplasia with globlet cells on esophageal biopsies,
* BE length C1M1 or C0M2
* Age 18 years

Exclusion Criteria:

* History of gastric or esophageal surgery
* Inability to give informed consent
* Erosive esophagitis seen on upper endoscopy
* History of prior endoscopic therapy for BE 5 (for controls) History of intestinal metaplasia on previous esophageal, GE junction or cardia biopsies.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: Abramson Cancer Center
state: Pennsylvania
Study officials:
affiliation: Abramson Cancer Center at Penn Medicine
name: Gary Falk, MD
role: PRINCIPAL_INVESTIGATOR
References: